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SUMMARY
Cancer cells often exhibit extreme sensitivity to splicing inhibitors. We identified food-derived flavo-
noids, apigenin and luteolin, as compounds that modulate mRNA splicing at the genome-wide level,
followed by proliferation inhibition. They bind to mRNA splicing-related proteins to induce a wide-
spread change of splicing patterns in treated cells. Their inhibitory activity on splicing is relatively
moderate, and introns with weak splice sites tend to be sensitive to them. Such introns remain un-
spliced, and the resulting intron-containing mRNAs are retained in the nucleus, resulting in the nuclear
accumulation of poly(A)+ RNAs in these flavonoid-treated cells. Tumorigenic cells aremore susceptible
to these flavonoids than nontumorigenic cells, both for the nuclear poly(A)+ RNA-accumulating pheno-
type and cell viability. This study illustrates the possible mechanism of these flavonoids to suppress
tumor progression in vivo that were demonstrated by previous studies and provides the potential
of daily intake of moderate splicing inhibitors to prevent cancer development.
INTRODUCTION
Messenger RNA processing (50 capping, splicing, and 30 end processing) is a fundamental step in eukary-
otic gene expression to sustain various cell functions, such as proliferation, survival, and differentiation (Ma-
niatis and Reed, 2002; Millevoi and Vagner, 2009; Orphanides and Reinberg, 2002). Among them, mRNA
splicing is a crucial process through which noncoding introns are removed from pre-mRNA by the spliceo-
some, composed of five snRNPs (small nuclear ribonucleoproteins: U1, U2, U4, U5, and U6 snRNPs) and an
assembly of accessory proteins (Hoskins and Moore, 2012; Wahl and Lu¨hrmann, 2015). This machinery rec-
ognizes short consensus sequences in the pre-mRNA, at the 50 splice site, the branchpoint sequence (BPS),
and the 30 splice site. Alternative splicing plays an important role in conferring remarkable variety on the
eukaryotic transcriptome through the differential usage of splice sites (Kim et al., 2014; Pan et al., 2008;
Wang et al., 2008). It has been suggested that abnormalities in mRNA splicing lead to many pathological
conditions, such as cancer onset and progression (Scotti and Swanson, 2016; Yoshida et al., 2011). For this
reason, the inhibition of inadequate splicing is attracting attention as an important therapeutic strategy
(Daguenet et al., 2015; Hahn et al., 2015; Maguire et al., 2015; Nlend Nlend et al., 2010; Salton and Misteli,
2016).
Various studies to detect compounds with inhibitory activity on splicing have been performed, and these
successfully identified several microorganism-derived compounds with activities that modulate mRNA
splicing (Effenberger et al., 2017). For example, spliceostatin A, pladienolide B, GEX1A, and H3B-8800
inhibit pre-mRNA splicing by disturbing spliceosome complex formation via binding to a component of
the SF3B complex, one of the constituents of U2 snRNP (Hasegawa et al., 2011; Kaida et al., 2007; Kotake
et al., 2007; Seiler et al., 2018).
Regarding food-derived compounds, epigallocatechin gallate, apigenin, and resveratrol were first identi-
fied by their inhibitory effects on the growth of cancer cells and later revealed to induce the alternative
splicing of several mRNAs (Arango et al., 2013; Markus et al., 2011; Sakla and Lorson, 2008). However,
only a few reports to date have been published on food-derived compounds with the ability to modulate
mRNA processing. Because various previous studies have focused on compounds with strong inhibitory
effects on splicing, the compounds with relatively moderate activity, such as food-derived compounds,
have been overlooked.
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In our established method, a relatively moderate inhibitory effect on mRNA processing can be captured as
bulk poly(A)+ RNA accumulation in the nucleus (Fujita et al., 2012; Fujiwara et al., 2010). Utilizing our
method, we previously screened food-derived compounds and identified mRNA processing inhibition
activities in the soybean-derived isoflavonoid fraction and performed further analysis that elucidated
that this activity was mainly exerted by compounds with a flavone skeleton (Kurata et al., 2016, 2017).
In this study, we assessed the activity of 21 compounds with a flavone skeleton to inhibit mRNA processing
and found that two of these flavonoids with highly related structures, namely, apigenin and luteolin, ex-
hibited the strongest activity. LC-MS/MS analysis of proteins bound to these compounds suggested
that their cellular targets are mRNA splicing-related proteins. RNA-seq data revealed that many alternative
splicing events were induced upon treatment with these flavonoids, strongly suggesting the effect of these
compounds on mRNA splicing. Further extensive analysis of the sequence features of target introns indi-
cated that these flavonoids tend to influence the splicing of introns with weak splice sites.
This study provides an effective approach to identify compounds exerting moderate inhibitory activity
against mRNA processing, with a particular emphasis on the usefulness of global analysis to clarify the
mechanisms underlying the perturbations induced by these compounds in mRNA processing. Using the
method described in this study, previously overlooked chemical libraries, such as those of food-derived
compounds, are worth revisiting as potential sources of compounds with moderate activity of modulating
mRNA processing.
RESULTS
Apigenin and Luteolin Exhibit Inhibitory Activity against mRNA Processing
Previously, we identified several flavonoids that have inhibitory activity against mRNA processing (Kurata
et al., 2016, 2017). In this study, we explored the structure-activity relationship of compounds with a flavone
skeleton by RNA-FISH (Figures 1 and S1). GEX1A, a well-known splicing inhibitor, was used as a positive
control. The structure of flavones contains a skeleton of diphenylpropane, namely, two benzene rings
(A-ring and B-ring) linked via a closed pyran ring (C-ring) with a benzenic A-ring. In addition, they have a
double bond between the 2 and 3 positions and a ketone at the 4 position of the C-ring. Among the
21 compounds tested, apigenin and luteolin exhibited the most intense and dose-dependent phenotype
of accumulating poly(A)+ RNA in the nucleus (Figures 2A–2C). These compounds harbor OH groups at the 5
and 7 positions of the A-ring, an OH group at the 40 position of the B-ring, and a double bond in the C-ring
as common structures, whereas an OH group at the 6 position of the A-ring, or the 20 or 50 position of the
B-ring, appears to eliminate the flavonoids’ activity on mRNA processing (Figures 1 and S1B). In apigenin-
and luteolin-treated cells, poly(A)+ RNAs mainly co-localized with SC35, a nuclear speckle marker protein,
indicating the accumulation of RNAs residing within the nuclear speckles (Figure 2D). This phenomenon
was also observed in cells treated with GEX1A.
mRNA Splicing Is a Candidate for the Cellular Target of Apigenin and Luteolin
The observed nuclear poly(A)+ RNA accumulation in apigenin- and luteolin-treated cells may reflect the
disruption of an mRNA export pathway (Lee et al., 2008). To examine this possibility, we assessed the
subcellular localization of transiently expressed b-globin mRNA in control cells and apigenin- or luteo-
lin-treated cells. Expressed reporter b-globinmRNA was visualized using Alexa Fluor 546-labeled b-globin
FISH probe (Figures 3A and 3B). Even in cells exhibiting a prominent phenotype of poly(A)+ RNA accumu-
lation in the nucleus induced by treatment with these flavonoids, b-globinmRNA was exported to the cyto-
plasm as efficiently as in control cells, indicating that the general mRNA export machinery is not disturbed
in these cells. In addition, the b-globin gene used in this assay contains introns with constitutive splice sites,
suggesting that this reporter mRNA properly undergoes splicing. Indeed, when we assessed the splicing of
this reporter mRNA, no obvious inhibition caused by these flavonoids was observed (Figure 3C). On the
other hand, it has been reported that apigenin and luteolin treatment alters the splicing pattern of Cas-
pase-9 and c-FLIP into an apoptosis-inducible form, thus inhibiting the proliferation of cancer cells (Arango
et al., 2013). Those previously described changes in splicing pattern, namely, the decreases in both
Caspase-9b, a variant with skipping of exons 3–6, and c-FLIPs, a variant with exon 7 instead of 8, were
also induced by apigenin and luteolin treatment in our experimental conditions, implying that these flavo-
noids have some effect on splicing (Figure 3D). Supporting the idea that apigenin and luteolin affect
splicing rather than export, the apigenin- and luteolin-derived nuclear speckle-associated poly(A)+ RNA
accumulation pattern was similar to that observed in cells depleted of SF3B1, a component of U2 snRNP
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Figure 1. Activity of Compounds with Flavone Skeleton Examined for mRNA Processing Inhibition
See also Figure S1.
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Figure 2. Inhibitory Activity against mRNA Processing of Apigenin and Luteolin
(A) Chemical structures of apigenin and luteolin.
(B) RNA-FISH was performed to determine the localization of bulk poly(A)+ RNA. U2OS cells were treated with the
indicated concentrations of each compound for 24 h GEX1A (30 ng/mL) was used as a positive control. The bulk poly(A)+
RNA was visualized by Alexa Fluor 594-labeled oligo-dT45 probe. The nuclei were visualized with DAPI. Scale bar, 50 mm.
(C) The ratio of the nuclear distribution of mRNA was analyzed. The signal intensities of the whole cell and the nucleus
were quantified using ImageJ (n = 35). Boxes show median (center line) and upper and lower quartiles. Whiskers show
the lowest and highest values. Statistical analysis was performed using one-way ANOVA followed by Dunnett’s test.
***p < 0.001.
(D) The localization of bulk poly(A)+ RNA and nuclear speckles. Poly(A)+ RNA (red), speckles (green), and chromosomal
DNA (blue) were visualized in U2OS cells for co-localization analysis. Cells were treated with each indicated compound
for 24 h. Scale bar, 10 mm. In right panels, signal intensities of poly(A)+ RNA and SC35 were plotted between a and b lines
in the left panels. Poly(A)+ RNA and SC35 signal are shown with red and green lines, respectively.
See also Figure S2.
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(Figure S2A), and was distinguishable from the uniform poly(A)+ RNA accumulation throughout the nucleus
observed in cells depleted of TAP (also known as NXF1), an mRNA exporter (Figure S2B) (Wang et al., 2018).
The subnuclear localization of accumulated poly(A)+ RNA observed in apigenin- and luteolin-treated cells
was also reminiscent of a phenotype exhibited by cells treated with spliceostatin A, a well-known splicing
Figure 3. The Effect on Splicing of Some Genes and Identification of Apigenin- and Luteolin-Targeted Proteins
(A) Schematic of b-globin construct containing the CMV promoter and BGH poly(A) site is presented. Horizontal lines
indicate introns, and boxes indicate exons.
(B) The localization of b-globinmRNA was observed. Bulk poly(A)+ RNA (green), b-globinmRNA (red), and chromosomal
DNA (blue) were visualized in U2OS cells. Scale bar, 10 mm.
(C) The splicing pattern of b-globin gene was observed by RT-PCR using total RNA. The digit panel below the photo
shows the percentage of unspliced mRNA band intensity and representative results of triplicate experiments. DNA size in
base pairs (b.p.) is indicated on the left side. Control: marker for unspliced b-globin mRNA. RT: reverse transcription.
(D) The change of splicing pattern of Caspase-9 and c-FLIP. RT-PCR was performed using total RNA. DNA size in base
pairs (b.p.) is indicated on the right side. The digit panels below the photo show the percentage of the indicated isoform
and representative results of triplicate experiments.
(E) Gene ontology analysis of proteins bound with apigenin or luteolin is shown. Proteins with protein score >0 in
Tables S1 and S2 were uploaded to the DAVID database for GO analysis.
See also Figures S2–S4.
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inhibitor, also implicating the mRNA splicing process as a cellular target of these flavonoids (Figure 2D)
(Carvalho et al., 2017; Kaida et al., 2007).
To explore the way in which these flavonoids influence poly(A)+ RNA metabolism in human cells, proteins
bound to apigenin and luteolin were analyzed. Flavonoid was fixed on magnetic FG beads with an epoxy
linker and was incubated with nuclear extract from HEK293 cells. Purified proteins were analyzed by LC-
MS/MS (Figures 3E, S3A, and S3B; Tables S1 and S2). The interaction between some of the LC-MS/MS-de-
tected proteins and either apigenin or luteolin was confirmed by the western blotting using specific anti-
bodies against these proteins (Figure S3C). Gene ontology analysis demonstrated that many of the de-
tected proteins have mRNA splicing-related functions (Figure 3E). Further detailed classification of the
splicing-related proteins according to a previous report indicated that these compounds most intensely
interact with U2 and U5 snRNP, components of the spliceosome (Figure S3B) (Hegele et al., 2012).
HNRNPA2B1, a protein that has been reported to interact with apigenin (Arango et al., 2013), was also
detected to a lesser extent than U2 and U5 snRNP components. To obtain insights into the interaction of
apigenin and luteolin with their potential targets, docking studies were performed using the crystal struc-
ture of human SF3B1, a component of the SF3B subcomplex in the U2 snRNP, in a complex with E7107, a
pladienolide derivative analog (PDB code: 5ZYA) (Finci et al., 2018). Our docking algorithm predicted
that apigenin and luteolin are likely to bind to SF3B1 near the E7107-binding site (Figure S4A). Both flavo-
noids interact with several hydrophobic residues such as Leu1066, Val1114, Val1110, and Lys1067, which are
also key residues for the hydrophobic interactions between E7107 and SF3B1 (Figure S4B). In addition, the
overexpression of SF3B1 attenuated the nuclear accumulation of poly(A)+ RNA induced by the apigenin-
and luteolin-treatment (Figure S4C). These results provide evidence that SF3B1 is one of the cellular targets
for apigenin and luteolin and plays a crucial role in the modulation of mRNA splicing by these flavonoids.
Taking these findings together, apigenin and luteolin bind to spliceosome components, and in the cells
treated with these compounds, changes in the splicing of at least some mRNAs can be effectively induced,
whereas the splicing of other mRNAs, such as the b-globin mRNA reporter, is less influenced. These
findings imply that apigenin and luteolin affect the splicing of a subset of introns, rather than generally in-
hibiting splicing reactions.
Apigenin and Luteolin Treatment Causes Numerous Alternative Splicing Events
To elucidate the effect of these flavonoids on mRNA splicing, we compared the poly(A)+ RNA profile in
flavonoid-treated cells with that in control cells using RNA-seq. Poly(A)+ RNA was purified from total
RNAs derived from either control cells or flavonoid-treated cells. RNA-seq reads were mapped with
STAR (Dobin et al., 2013) against the hg38 human genome and to the obtained mapping data; we applied
rMATS, a bioinformatic tool, to detect alternative splicing events (Figure 4A) (Shen et al., 2014). We de-
tected a wide variety of alternative splicing events induced by treatment with either flavonoid (Figures
4B and 4C). Among the altered splicing patterns, retained intron (RI) was the most frequently detected, fol-
lowed by skipped exon (SE). Since apigenin and luteolin have similar structures and binding proteins, we
hypothesized that they commonly regulate mRNA splicing. To investigate the regulatory mechanism
involved, we focused on their common events (Figures 4D and S5). Specifically, we performed gene
ontology analysis on the events overlapping between apigenin- and luteolin-treated cells (Figures 4E
and S5), indicating that the mRNAs with the retention of introns due to these flavonoids are particularly
associated with RNA processing, mRNA metabolic process, and mRNA splicing. RT-PCR using cDNA
generated from total RNA successfully confirmed some of the apigenin- and luteolin-derived RIs and
another alternative splicing event identified in our rMATS analysis, whereas neither tricetin nor naringenin
induced these changes. This demonstrated the significance of the specific structure within these flavonoids
for their ability to exert such activity (Figures 4F and S6). Previous studies suggested that unspliced mRNAs
are inefficiently exported to the cytoplasm, leading to poly(A)+ RNA accumulation in nuclear speckles
(Johnson et al., 2000; Kaida et al., 2007). Based on these findings, we hypothesized that a phenotype
derived from apigenin and luteolin treatment, namely, the nuclear speckle-associated poly(A)+ RNA accu-
mulation, reflects nuclear-retained mRNAs with introns. Therefore, we focused on the RIs for further
investigation.
Apigenin- and Luteolin-Induced Alternative Splicing Leads to a Change in Gene Expression
Taking into account the possibility that mRNAs with RIs are less effectively exported to the cytoplasm, it was
assumed that the expression of genes with apigenin- and luteolin-sensitive introns decreases upon
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Figure 4. Global Analysis of mRNA Splicing Affected by Apigenin and Luteolin
(A) Alternative splicing analysis scheme. Cells were treated with DMSO, apigenin (75 mM), or luteolin (75 mM) for 24 h; then,
total RNA was extracted from the cells. Next, poly(A)+ RNA was purified and fragmented for RNA sequencing. Alternative
splicing analysis was performed using rMATS.
(B) Alternative splicing analysis revealed five alternative splicing patterns that were output by rMATS. Upper row indicates
the numbers of total splicing events detected in each alternative splicing pattern; bottom row indicates the numbers of
statistically significant (false discovery rate: FDR <0.05) splicing pattern changes upon apigenin (blue) or luteolin
treatment (green).
(C) Frequency of splicing pattern changes by apigenin or luteolin relative to the total splicing events is calculated using
the data in (B).
(D) Venn diagram shows the numbers of apigenin- or luteolin-induced retained intron events.
(E) Gene ontology analysis of apigenin- and luteolin-induced retained intron events. Common target genes of apigenin
and luteolin (the number shown in bold in Figure 4D) were uploaded to the DAVID database for GO analysis. Apigenin-
and luteolin-targeted genes in U2OS cells were enriched for several GO terms categorized in ‘‘Biological Process.’’ Ten
GO terms are listed in order of their p values. The ‘‘Count’’ column denominator indicates the number of genes assigned a
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treatment with these flavonoids. To test this hypothesis, we fractionated the cytoplasmic RNA (Figure S7A).
Our RT-PCR analysis clearly detected RIs caused by the treatment with these flavonoids in the whole-cell
fractions, but not in the cytoplasmic fractions, indicating that mRNAs harboring those introns are not ex-
ported to and/or eliminated in the cytoplasm (Figure 5A). A significant decrease in the expression of genes
whose splicing is inhibited by apigenin and luteolin treatment was demonstrated for thematuredmRNAs in
the cytoplasm (Figure 5A), as well as at the protein level (ANKZF1, PSMA1, and ZWINT) (Figure S7B). In
contrast, SEs triggered by apigenin and luteolin treatment were efficiently detected in either fraction (Fig-
ure S7C), indicating that these mRNAs associated with exon skipping are efficiently exported to the cyto-
plasm. Neither the splicing nor the cytoplasmic expression level of nontarget introns appeared to be
affected following treatment with apigenin and luteolin.
Intron retention often produces premature termination codon (PTC) that makes the associated coding
mRNAs sensitive to nonsense-mediated mRNA decay (NMD) in the cytoplasm (Ge and Porse, 2014).
Indeed, we found PTCs within apigenin- and luteolin-derived unspliced mRNAs (Figure 5B). The absence
of these unspliced mRNAs in the cytoplasmmight be explained by the intense susceptibility of these RNAs
to NMD, besides the retention of RNAs within the nucleus. To discriminate between these two possibilities,
an NMD assay was performed (Figure 5B). In the cytoplasmic fraction, a PTC-containing transcript variant of
SRSF2, a well-known NMD target (Feng et al., 2015), was detected only in the presence of cycloheximide
(CHX), an NMD inhibitor, demonstrating disturbed NMD under these conditions. In contrast, unspliced
mRNAs caused by apigenin and luteolin were not detected irrespective of the integrity of NMD, indicating
that apigenin- and luteolin-elicited unsplicedmRNAs are eliminated from the cytoplasmmainly by their nu-
clear retention, rather than by the digestion in the cytoplasm.
Taking these findings together, as a consequence of various alternative splicing events, such as the nuclear
retention of unspliced mRNAs and the expression of exon skipping-caused transcript variants, these flavo-
noids induce a change in the cytoplasmic transcriptome.
Apigenin and Luteolin Inhibit Splicing of Introns with Weak Splice Sites
To characterize introns whose splicing is affected by apigenin and luteolin, we compared their intron
length, GC content, splice site score, and BPS score with those of all of the introns annotated in the human
genome (Figure 6A). Splice site score was calculated using MaxEntScan (Yeo and Burge, 2004). The BPS
score was calculated using the SVM-BP program (Corvelo et al., 2010). The results suggested that RIs
caused by apigenin and luteolin treatment are shorter, have weaker 50 and 30 splice sites, and show higher
GC content, whereas the BPS scores are similar between these flavonoid-target and nontarget introns.
To confirm the significance of weak splice sites for the susceptibility to these flavonoids, sequences of 50
and 30 splice sites within introns of interest were manipulated to display a higher splice site score, and it
was examined whether the splicing of these engineered introns is still sensitive to apigenin and luteolin.
For this purpose, introns accompanied by portions of both neighboring exons were cloned into an expres-
sion vector, and these vectors were transiently transfected into U2OS cells, achieving the expression of
these reporter RNAs under the control of the CMV promoter. We successfully obtained several mini genes,
PLXNB1, PSMA1, and ANKZF1, which can efficiently reproduce apigenin- and luteolin-induced intron
retention exhibited by the endogenous genes (Figure 5A). Mutating the splice sites of the introns in these
mini genes to raise the splice sites with a higher score, namely, changes of 1.11/6.99 or 1.11/9.46 in the
30 splice site score (30 ss score) of the PLXNB1mini gene,5.12/9.07 in the 50 splice site score (50 ss score),
9.15/9.66 in the 30 ss score in the PSMA1mini gene, and 0.11/10.45 in the 50 ss score in the ANKZF1
mini gene, almost abolished their responses to apigenin and luteolin (Figures 6B, 6C, and S8). In addition,
Figure 4. Continued
DAVID ID among the uploaded target genes of apigenin and luteolin in retained intron events. The numerator
indicates the number of genes associated with each GO term.
(F) Validation of retained introns regulated by apigenin and luteolin. In the upper panels, IGV snapshots of retained
introns induced by apigenin (blue) and luteolin (green) are shown. Gene structure is depicted at the bottom of each
snapshot, with horizontal lines indicating introns and boxes indicating exons. Red square lines surrounding introns
indicate regions affected by apigenin and luteolin. Lower panels: RT-PCR was performed using total RNA samples to
detect apigenin- or luteolin-induced retained introns. Representative results of triplicate experiments are shown. DNA
size in base pairs (b.p.) is indicated on the left side. RT: reverse transcription. M: DNA size marker.
See also Figures S5 and S6.
iScience 22, 336–352, December 20, 2019 343
Figure 5. The Expression Level of Retained Intron-Containing mRNA in the Cytoplasm
(A) Detection of retained intron events in the cytoplasm after apigenin and luteolin treatment. RT-PCR was performed using total RNA and cytoplasmic RNA.
DNA size in base pairs (b.p.) is indicated on the left side. Non-targeted introns that are not regulated by apigenin and luteolin are shown at the bottom of (A).
Representative results of triplicate experiments are shown. To compare the mRNA expression in cytoplasmic fractions, RT-qPCR was performed using
cytoplasmic RNA. Values represent the relative expression of the indicated mRNA normalized to TBP. Each value is mean G SD of three independent
experiments. Statistical analysis was performed using one-way ANOVA followed by Dunnett’s test. ***p < 0.001, n.s.: not significant.
(B) The effect of nonsense-mediated decay (NMD) onmRNAwith retained intron in the cytoplasmic fraction was examined. Cycloheximide (CHX) was used as
an NMD inhibitor. U2OS cells were treated with CHX (50 mg/mL) in the presence of apigenin (75 mM) or luteolin (75 mM) for 24 h. RT-PCR products of variant
transcripts were detected. The digit panels below the photo shows the percentage of unspliced mRNA band intensity and representative results of triplicate
experiments. Blue circle indicates a reference stop codon, and red circle indicates a premature termination codon (PTC). PTC + means that the transcript
variant has PTC. SRSF2, a well-known target of NMD, was used as a positive control (Feng et al., 2015). Dotted region in the SRSF2 figure indicates protein-
coding sequence, and primer locations (black arrows) are marked on the SRSF2 gene.
See also Figure S7.
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the PLXNB1mini gene with its 30 ss mutated to achieve a moderate score of 6.99 still exhibited subtle sus-
ceptibility to these flavonoids. The efficiencies of either apigenin or luteolin treatment in these experiments
were confirmed by RT-PCR analysis of the endogenous mRNAs from the same samples transiently express-
ing each reporter mini gene (Figures 6B, 6C, and S8). And as mentioned above, the b-globin reporter indi-
cated that its transcript escaped from flavonoid-induced splicing inhibition (Figures 3B and 3C). These find-
ings suggest that weak splice sites are crucial for an intron’s susceptibility to apigenin and luteolin.
Apigenin- and Luteolin-Derived Unspliced mRNAs Accumulate at Nuclear Speckles
Next, we assessed the subcellular localization of these mini gene-derived mRNAs in the presence or
absence of apigenin and luteolin to examine whether the nuclear accumulation of bulk poly(A)+ RNAs
observed in the flavonoid-treated cells contains the flavonoid-caused unspliced mRNAs. To visualize
these reporter mRNAs, a sequence complementary to the b-globin FISH probe used as shown in Fig-
ure 3A was inserted into either the PLXNB1 or PSMA1 mini gene. RT-PCR analysis demonstrated that
b-globin sequence-fused mini genes maintained their response to the flavonoids (Figure 7A). The re-
sults also showed that mutating the splice sites to have a higher score abolished their response to
the flavonoids, as observed with native sequence reporters (Figures 6B, 6C, and 7A). In either apige-
nin-/luteolin-treated or untreated cells, these mini genes were transiently expressed and visualized by
FISH using b-globin probe (Figure 7B). Bulk poly(A)+ RNA was simultaneously visualized in the same
cells to verify the effect of the treatment with flavonoids. In DMSO-treated cells, expressed reporter
mRNAs were efficiently exported to the cytoplasm. In apigenin- and luteolin-treated cells, WT re-
porter mRNAs were diminished from the cytoplasm and accumulated in the nucleus, whereas apige-
nin- and luteolin-insensitive mutated mRNAs were efficiently exported to the cytoplasm under these
conditions. Notably, in the flavonoid-treated nucleus, WT mRNA reporters co-localized with bulk
poly(A)+ RNAs, indicating that flavonoid-caused unspliced reporter mRNAs accumulate at the nuclear
speckles.
Tumorigenic Cells Exhibit More Prominent Sensitivity to Apigenin and Luteolin than Non-
tumorigenic Cells
It has been shown that cancer cells are more sensitive to reagents inhibiting splicing (see Discussion)
(Dvinge et al., 2016). We thus assessed whether this is also the case with apigenin and luteolin by comparing
their effects on U2OS, HeLa, and MCF7 tumorigenic cell lines with those on non-tumorigenic HaCaT cells.
When added at 75 mM, apigenin and luteolin caused prominent nuclear poly(A)+ RNA accumulation in all of
the tumorigenic cell lines tested, whereas the nuclear poly(A)+ RNA accumulation in HaCaT cells under the
same conditions was moderate (Figure 8A). In addition, tumorigenic cells exhibited a steeper dose
response than HaCaT cells.
We also examined the effect of these compounds on the cell viability (Figures 8B and S9). These flavonoids
significantly inhibited the proliferation of U2OS cells in a dose- and time-dependent manner. HaCaT cells
also exhibited a dose- and time-dependent response to these flavonoids but to a lesser extent than U2OS
cells at all doses and time points. Other non-tumorigenic cells, WI-38 and TIG-1, also gave similar results
with HaCaT cells. Taken together, apigenin and luteolin seem to be more effective for tumorigenic cells
than for non-tumorigenic cells (Figure S9).
Figure 6. Apigenin and Luteolin Induce Intron Retention with Weak Splice Sites
(A) The bioinformatic analysis on retained introns induced by apigenin and luteolin. All introns of human reference genes and retained introns induced by
apigenin and luteolin were analyzed. Boxes show median (center line) and upper and lower quartile ranges. Whiskers show the lowest and highest values.
Statistical analysis was performed using the two-sided Mann–Whitney U test. *p < 0.05, ***p < 0.001, n.s.: not significant.
(B and C) Upper left panels in (B and C) present schematic representations of mini gene constructs affected by apigenin and luteolin. The CMV promoter and
BGH poly(A) sites are shown. Jagged line in the figure of the exon indicates that the edges of the exons have been partially deleted in order to distinguish
endogenousmRNA from transgene-derivedmRNA. Themutated nucleotides in eachmutated-mini gene construct are shown in red, and the exon sequence
is shown in upper case. Splice site score (ss score) was calculated using MaxEntScan. Lower left panels in (B and C) present schematic representations of the
endogenous gene. The locations of the primers that amplify the endogenous target are marked in the schematic representation of the endogenous gene
(black arrows). Right panels in (B and C) show the results of RT-PCR. DNA size in base pairs (b.p.) is indicated on the left side. The mRNAs derived from the
transgene are shown in the upper right panels, and endogenous mRNAs are shown in the lower right panels. The digit panels below the photo show the
percentage of unspliced mRNA band intensity and representative results of triplicate experiments.
See also Figure S8.
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DISCUSSION
Food not only provides nutrition, taste, and texture but also regulates biological function. The daily intake
of bioactive food compounds is expected to be effective for the prevention of chronic diseases. For
example, polyphenols and carotenoids have antioxidant activity and function in preventing lifestyle-related
diseases (Pandey and Rizvi, 2009; Reinisalo et al., 2015; Young and Lowe, 2001). Flavonoids, which are abun-
dant in fruit and vegetables, have been reported to reduce the risk of lifestyle-related diseases and carci-
nogenesis (Bo et al., 2016; Lo´pez-la´zaro, 2009). Despite the broad bioactivity of flavonoids, few studies on
their regulatory activity against mRNA processing, especially splicing, have been reported. We previously
searched for compounds derived from food that have the ability to inhibit mRNA processing and identified
such effects in compounds with a flavone skeleton (Kurata et al., 2016, 2017).
In this study, we have shown that, among the flavonoids, apigenin and luteolin have remarkable activity of
inhibiting mRNA processing. Several lines of evidence indicate that this activity is derived from the direct
inhibition of splicing. Our rMATS analysis demonstrated that all types of alternative splicing events are pro-
voked by treatment with apigenin and luteolin, and the retention of introns is the event having the highest
frequency. It was previously shown that splicing inhibition by either spliceostatin A treatment or the knock-
down of a component of U2 snRNP or U5 snRNP, such as SF3B1 or PRPF8, causes the retention of numerous
introns in mRNAs coding RNA processing factors (Wickramasinghe et al., 2015; Yoshimoto et al., 2016),
implying that these mRNAs are highly sensitive to splicing inhibition. Such enrichment of RNA processing
factors, especially of mRNA splicing, was also observed in the genes that we identified to harbor introns
whose retention was induced by apigenin and luteolin. It has been reported that unspliced mRNAs result-
ing from the global inhibition of splicing by spliceostatin A treatment manifest as a robust accumulation of
bulk poly(A)+ RNAs at the nuclear speckles (Carvalho et al., 2017; Kaida et al., 2007). Similarly, we observed
that apigenin and luteolin treatment induced the accumulation of bulk poly(A)+ RNA, as well as the reten-
tion of intron-containing transcripts from target mini genes, in the nuclear speckles, implying that these fla-
vonoids affect a broad range of mRNA splicing events. Our results from LC-MS/MS, docking studies and
SF3B1 overexpression analysis simply suggest that these flavonoids interact with U2 and U5 snRNP,
possibly through the interaction with SF3B1, to modulate mRNA splicing, although we cannot exclude
other possible splicing regulatory mechanisms by these flavonoids, such as SUMOylation of spliceosomal
components previously reported for an apigenin- and luteolin-related biflavonoid, hinokiflavone (Pawellek
et al., 2017). Together, these findings suggest that apigenin and luteolin associate with spliceosomal com-
ponents to directly prevent the function of spliceosomes, thus affecting alternative splicing at the genome-
wide level.
Our rMATS analysis did not detect previously demonstrated alternative splicing events induced by apige-
nin and luteolin treatment, such as the change of splicing pattern of Caspase-9 and c-FLIPmRNA (Arango
et al., 2013), although it was efficiently recapitulated by RT-PCR analysis, indicating that these flavonoids
actually affect a broader range of splicing events beyond our criteria of rMATS analysis. Such events
may include the very subtle splicing perturbation that, if it occurs to numerous targets, can contribute to
the flavonoid-induced nuclear bulk poly(A)+ RNA accumulation.
Our data also illustrated a mechanism by which these flavonoids inhibit splicing. The bioinformatic analysis
raises the possibility that weak splice sites are a general feature for the retention of introns caused by
apigenin and luteolin. Supporting this hypothesis, manipulating the splice site score in the target introns
abolished their sensitivity to these flavonoids and led them to be spliced out. Therefore, apigenin and lu-
teolin presumably perturb the association of splicing-related factors with the weak splice sites to inhibit
splicing.
We observed more sensitivity of tumorigenic cells to apigenin and luteolin than that observed for non-
tumorigenic cells, both for the bulk mRNA processing and cell viability. The exact relationship between
Figure 7. Localization of mRNAs with Retained Intron Induced by Apigenin and Luteolin
(A) Schematic of mini gene constructs with b-globin FISH probe tag. The CMV promoter and BGH poly(A) sites are shown. DNA size in base pairs (b.p.) is
indicated on the left side. The digit panels below the photo show the percentage of unspliced mRNA band intensity and representative results of triplicate
experiments.
(B) The localization of target mRNA was observed. Bulk poly(A)+ RNA (green), target mRNA (red), and chromosomal DNA (blue) were visualized in U2OS
cells. Scale bar, 10 mm.
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Figure 8. Inhibition of mRNA Processing and Proliferation of Tumorigenic Cells by Apigenin and Luteolin
(A) Bulk poly(A)+ RNA (red) and chromosomal DNA (blue) were visualized in HeLa, MCF7, and HaCaT cells. Cells were treated with the indicated
concentrations of each compound for 24 h. Scale bar, 50 mm. In lower panels, the signal intensities of bulk poly(A)+ RNA in the whole cell and in the nucleus
iScience 22, 336–352, December 20, 2019 349
splicing and cancer progression is still unclear. However, splicing abnormality has been found to be
involved in the onset and progression of various cancers (Scotti and Swanson, 2016; Sveen et al., 2016),
and it has been suggested that cancers harboring mutations in splicing factors are highly susceptible to
splicing inhibition (Lee et al., 2016). For example, acute myeloid leukemia cells with SF3B1mutation exhibit
reduced viability in the presence of a splicing inhibitor (Seiler et al., 2018). High sensitivity to splicing
inhibition has also been demonstrated for cancers caused by c-Myc oncogene overexpression (Hsu
et al., 2015). In this case, it has been suggested that massive amounts of c-Myc-driven pre-mRNA sequester
a substantial population of spliceosomes to weaken the splicing activity available for endogenous
pre-mRNAs, thus conferring on cells similar sensitivity for splicing inhibition as observed in cancer cells re-
sulting from mutations in splicing factors. Hence, splicing inhibitors are attractive candidates for anti-can-
cer drugs. Indeed, splicing inhibitors such as H3B-8800 (Seiler et al., 2018) are under clinical trials for anti-
cancer therapy. Because the concentrations at which apigenin and luteolin can effectively exert their
splicing-inhibiting activities are much higher than those of previously identified compounds, such as spli-
ceostatin A and H3B-8800, the employment of these flavonoids as anti-cancer drugs may not be so prom-
ising. Nonetheless, further evaluation of these flavonoids as anti-cancer drugs should be conducted. On
the other hand, it has been reported that xenograft progression of human tumors was repressed by the
oral administration of apigenin or luteolin into nude mice (Li et al., 2018; Shukla et al., 2015; Xu et al.,
2018) and that the daily intake of bulk flavonoids reduced carcinogenesis in humans (Bo et al., 2016; Lo´-
pez-la´zaro, 2009). These findings suggest a beneficial effect of these compounds on preventing cancer
development when they are consumed in food on a daily basis for a considerable period.
Many screening systems to identify anti-cancer compounds are highly focused on finding compounds with
strong activity. Therefore, compounds with moderate activity have been overlooked. Our study provides an
effective strategy to discover compounds harboring moderate inhibitory activity on mRNA processing and to
elucidate the mechanism underlying the disruption of mRNA processing induced by candidate compounds.
Limitations of the Study
We have revealed the underlying mechanism that food-derived compounds apigenin and luteolin cause
intron retention. Other than intron retention, we also observed various alternative splicing events induced
by these flavonoids and whether an analogous molecular mechanism contributes to these events remains
to be assessed.
A hypersensitivity of cancer cells to the splicing inhibition has been shown in many studies, implying our
observed in vitro inhibition of cancer cell proliferation by apigenin and luteolin, as well as the previously
demonstrated suppression of human tumor xenograft progression by apigenin-treatment in a mouse
model, is derived from the inhibited splicing. However, a further investigation should be required to eluci-
date a direct relationship between these flavonoids’ inhibitory activity on splicing and their exhibited tumor
growth suppressive effect.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
DATA AND CODE AVAILABILITY
The RNA-seq data were submitted to Gene Expression Omnibus (accession number: GSE128097). Original
imaging data have been deposited to Mendeley Data and are available at https://doi.org/10.17632/
t6r9jftdnr.1.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.11.033.
Figure 8. Continued
were quantified using ImageJ (n = 35). Boxes show median (center line) and upper and lower quartiles. Whiskers show the lowest and highest values.
Statistical analysis was performed using one-way ANOVA followed by Dunnett’s test. ***p < 0.001.
(B) Proliferation of U2OS and HaCaT cells treated with the indicated concentrations of each compound for 24, 48, or 72 h. Cell viability was determined by
MTT assay. Cell viability in comparison with that of DMSO-treated cells, which was set to 100%, is reported as meanG SD of six independent experiments.
See also Figure S9.
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Figure S1. Accumulation of poly(A)+ RNA by the indicated chemical compounds with a 
flavone skeleton. (Related to Figure 1) 
(A) mRNA processing inhibitory activity of chemical compounds with a flavone skeleton. The ratio 
of nuclear distribution of mRNA is shown. The signal intensities of bulk poly(A)+ RNA in the 
whole-cell and in the nucleus were quantified using ImageJ (n = 35). Boxes show median (center 
line) and upper and lower quartiles. Whiskers show the lowest and highest values. Statistical 
analysis was performed using one-way ANOVA followed by Dunnett’s test. *p < 0.05, **p < 0.01, 
***p < 0.001. 




Figure S2. Localization of poly(A)+ RNA in cells depleted of splicing factor, SF3B1, and 
mRNA exporter, TAP. (Related to Figures 2 and 3) 
(A) and (B)  Localization of poly(A)+ RNA in U2OS cells. Poly(A)+ RNA localization (red) was 
observed in SF3B1 (A) and TAP (B) knockdown conditions. SC35 (green) was used to stain the 
nuclear speckle. DAPI (blue) was used to visualize the nuclei. Scale bar, 10 μm. In right panels, 










Figure S3. Detection of apigenin- and luteolin-binding proteins. (Related to Figure 3) 
(A) Apigenin- and luteolin-binding proteins were purified from the nuclear extracts of HEK293 cells 
with unfixed (−) or flavonoid-fixed FG beads and were analyzed by silver staining. The binding 
proteins were analyzed by LC-MS/MS. M: Protein size marker. 
 (B) Splicing-related proteins binding to apigenin or luteolin. Prot_scores of control and apigenin- 
and luteolin-target proteins in Tables S1 and S2 were calculated using Mascot software (Matrix 
Science). Protein score is obtained by subtracting the prot_score of the control from that of 
apigenin or luteolin. Splicing-related proteins with protein score > 0 were extracted. When 
multiple protein scores were calculated for one protein, the highest value is listed. In the lower 
right bar, higher color intensity indicates a higher protein score. “Low” represents the lowest 
value, and “High” represents the highest value among the protein scores of splicing-related 
proteins. The black arrow indicates the average value of each protein score. 
(C) Apigenin- and luteolin-binding proteins in HEK293 cells (left) and U2OS cells (right) were 
analyzed by western blotting. Naringenin was used as a negative control. The antibodies are 




Figure S4. Binding of apigenin and luteolin in SF3B1. (Related to Figure 3) 
(A)  The crystal structure of human SF3B1 and E7107 was retrieved from the RCSB protein data 
bank (PDB code 5ZYA). The potential binding site of apigenin and luteolin in the SF3B complex 
was searched for and detected in the pocket near the branch point adenosine recognition site. 
The putative binding modes of apigenin and luteolin are displayed in sky blue and yellow, 
respectively.  
(B)  The simulation predicted that both apigenin and luteolin interact with several hydrophobic 
residues such as Leu1066, Val1114, Val1110, and Lys1067 of SF3B1. The Lys1071, Arg1074, 
 and Arg1075 are also the key residues for the hydrophobic interaction between E7107 and 
SF3B1, and are located near the BPA recognition site (Finci et al., 2018). 
(C)  The overexpression of FLAG-SF3B1 attenuated the flavonoid-induced nuclear poly(A)+ RNA 
accumulation. Poly(A)+ RNA (red), exogenously expressed FLAG-SF3B1 (green), and 




Figure S5. Gene ontology analysis of apigenin- and luteolin-induced A3SS, A5SS, MXE, and 
SE. (Related to Figure 4) 
Common target genes of apigenin and luteolin (the number shown in bold) were uploaded to the 
DAVID database for GO analysis. Apigenin- and luteolin-target genes in U2OS cells were enriched 
for several GO terms categorized into “Biological Process.” Ten GO terms are listed in order of their 
p values. The denominator of the “Count” column indicates the number of genes assigned a DAVID 
ID among the uploaded target genes of apigenin and luteolin in each alternative splicing event. The 




Figure S6. Validation of A3SS, A5SS, SE, and MXE regulated by apigenin and luteolin. 
(Related to Figure 4) 
In the left panels, IGV snapshots of A3SS, A5SS, SE, and MXE induced by apigenin (blue) and 
luteolin (green) are shown. Gene structure is depicted at the bottom of each snapshot with horizontal 
lines indicating introns and boxes indicating exons. Red square lines surrounding alternative exons 
indicate regions affected by apigenin and luteolin. As shown in the right panels, RT-PCR was 
performed using total RNA samples in order to detect the apigenin- or luteolin-induced alternative 
splicing change. Representative results of triplicate experiments are shown. DNA size in base pairs 
(b.p.) is indicated on the left side. RT: reverse transcription. M: DNA size marker. 
  
 
Figure S7. Expression of mRNA with altered splicing pattern in the cytoplasm. (Related to 
Figure 5) 
(A) Fractionation of the nuclear, cytoplasmic, and total RNA was carried out. tRNA was detected as 
a dominant RNA species in the cytoplasmic fraction. E2F8 mRNA was used to confirm that the 
fractionation had been successfully performed. U6 snRNA served as a nuclear marker. DNA 
size in base pairs (b.p.) is indicated on the right side. To: total RNA, Nu: nuclear RNA, Cy: 
cytoplasmic RNA. M: DNA size marker. RT: reverse transcription. 
(B) Effect of flavonoids on protein expression. The U2OS cells were treated with apigenin or luteolin 
(75μM) for 24 h. Total cell extracts were subjected to SDS-PAGE and analyzed by Western 
blotting. Representative blots are shown. The antibodies are indicated on the right side of each 
panel. 
(C) Skipped exon induced by apigenin and luteolin treatment was detected using total RNA and 
cytoplasmic RNA by RT-PCR. The digit panels below the photo show the percentage of exon 
skipping band intensity and representative results of triplicate experiments. 
  
 
Figure S8. Apigenin and luteolin induce intron retention with weak splice sites. (Related to 
Figure 6) 
The upper left panel presents a schematic representation of mini gene constructs affected by apigenin 
and luteolin. The CMV promoter and BGH poly(A) sites are shown. Jagged line in the figure of the 
exon indicates that the edges of the exons have been partially deleted in order to distinguish 
endogenous mRNA from transgene-derived mRNAs. The mutated nucleotides in each mutated-mini 
gene construct are shown in red, and the exon sequence is shown in upper case. The splice site (ss) 
score was calculated using MaxEntScan. The lower left panel presents a schematic representation 
of the endogenous gene. The locations of the primer that amplify the endogenous target are marked 
on the schematic representation of the endogenous gene (black arrows). Right panels show the 
results of RT-PCR. DNA size in base pairs (b.p.) is indicated on the left side. The mRNAs derived 
from the transgene are shown in the upper right panels, and endogenous mRNAs are shown in the 
lower right panels. The digit panels below the photo show the percentage of unspliced mRNA band 




Figure S9. Inhibition of the proliferation in non-tumorigenic cells by apigenin and luteolin. 
(Related to Figure 8) 
The proliferation of non-tumorigenic cells, WI-38 and TIG-1, treated with the indicated concentrations 
of each compound for 24 or 48 h and compared with that of U2OS cells. Cell viability was determined 
by MTT assay. Cell viability in comparison with that of DMSO-treated cells, set to 100%, is reported 
as mean ± SD of six independent experiments. 
 
  




The sequence of siRNAs in this study. (Related to Figure S2)  
 
Name Nucleotide sequence  Source 
EGFP GGGCACAAGCUGGAGUACAACUACA Invitrogen 
TAP GAACUGGUUCAAGAUUACAAUUCCU Invitrogen 
 
SF3B1 siRNA was predesigned by IDT. The catalog number is hs.Ri.SF3B1.13.1. 
 TRANSPARENT METHODS 
Cell culture 
U2OS, HeLa, MCF7, HaCaT, and HEK293 cells were maintained in Dulbecco’s Modified Eagle 
Medium (Wako, Kyoto, Japan) supplemented with 10% heat-inactivated fetal bovine serum at 37°C. 
WI-38 and TIG-1 cells were maintained in Eagle's minimum essential medium (Wako) 
supplemented with 10% heat-inactivated fetal bovine serum at 37°C. 
 
Antibodies 
The commercial antibodies used were as follows: anti-SF3B1 mouse monoclonal antibody (1:1000 
dilution) (a kind gift from Robin Reed, Ph.D.), anti-U2AF65 mouse monoclonal antibody (1:1000 
dilution) (also from Robin Reed, Ph.D.), anti-β-actin mouse monoclonal antibody (1:2000 dilution) 
(Sigma-Aldrich, St. Louis, MO), anti-SC35 mouse monoclonal antibody (1:2000 dilution) (Sigma-
Aldrich), anti-FLAG M2 monoclonal antibody (1:1000 dilution) (Sigma-Aldrich), anti-ANKZF1 (1:500 
dilution) (GeneTex, Irvine, CA), anti-PSMA1 (1:2000 dilution) (GeneTex), and anti-ZWINT (1:2000 
dilution) (GeneTex). Anti-UAP56 rat polyclonal antibody, as described previously, was also used 
(Yamazaki et al., 2010). 
 
Fluorescence in situ hybridization (RNA-FISH) 
Cells (5 × 104 cells/mL) on coverslips in a 12-well plate were cultured for 24 h following inoculation, 
fixed with 10% formaldehyde in phosphate-buffered saline (PBS) for 20 min, and permeabilized in 
0.1% Triton X-100 in PBS for 10 min. Cells were washed three times with PBS for 10 min to remove 
the detergent, once with 2× standard sodium citrate (SSC) for 5 min to exchange the buffer content, 
prehybridized with ULTRAhyb-Oligo Hybridization Buffer (Ambion, Austin, TX) for 1 h at 42°C in a 
humidified chamber, and then incubated overnight with 10 pmol Alexa Fluor 594-labeled oligo-dT45 
probe (Molecular Probes, Eugene, OR) diluted with hybridization buffer. Cells were washed for 20 
min each at 42°C with 2× SSC, 0.5× SSC, and 0.1× SSC. The nuclei were visualized with 4’, 6-
diamidino-2-phenylindole (DAPI). Fluorescent images were captured at random using a Zeiss 
Axioplan 2 (Carl Zeiss, Jena, Germany), equipped with an OLYMPUS DP70 camera (OLYMPUS, 
Tokyo, Japan). Confocal images were obtained by a FLUOVIEW FV10i microscope (OLYMPUS). 
The ratio of nuclear to total poly(A)+ RNA signals was calculated using ImageJ software 
 (https://imagej.nih.gov/ij/) (version 1.51w), in accordance with the instructions. 
 
Immunofluorescence 
After RNA-FISH, the cells were washed once with PBS and then blocked with 6% bovine serum 
albumin (BSA) in PBS for 1 h at room temperature. The coverslips were incubated with the primary 
antibody in PBS containing 2% BSA, followed by secondary antibodies labeled with Alexa Fluor 
488. Nuclei were visualized with DAPI.  
 
Preparation of nuclear extracts 
HEK293 or U2OS cells were centrifuged, washed twice with PBS, and very carefully suspended in 
double the pellet volume of hypotonic buffer [10 mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 
0.2 mM phenylmethylsulfonyl fluoride (PMSF), 0.5 mM dithiothreitol (DTT)]. The cells were kept on 
ice for 10 min, and the cell lysate was obtained by homogenization with a Dounce homogenizer 
(Wheaton, Millville, NJ). The cell lysate was collected by centrifugation at 13,000×g for 1 min. Half 
of the pellet volume of low-salt buffer [20 mM HEPES (pH 7.9), 1.5 mM MgCl2, 20 mM KCl, 0.2 mM 
EDTA, 25% glycerol, 0.2 mM PMSF, 0.5 mM DTT] was then added to the pellet. After suspending 
the pellet, the same volume of high-salt buffer [20 mM HEPES (pH 7.9), 1.5 mM MgCl2, 1.4 M KCl, 
0.2 mM EDTA, 25% glycerol, 0.2 mM PMSF, 0.5 mM DTT] was added dropwise. The cell lysate was 
gently mixed by rotating at 4°C for 30 min and then centrifuged at 20,000×g for 15 min. The 
supernatant was collected and dialyzed for 3 h using dialysis buffer [20 mM HEPES (pH 7.9), 100 
mM KCl, 0.2 mM EDTA, 20% glycerol, 0.2 mM PMSF, 0.5 mM DTT]. 
 
Construction of flavonoid-conjugated beads 
Flavonoid was fixed with magnetic FG beads with an epoxy linker (Tamagawa Seiki, Iida, Japan) in 
the following way. In brief, flavonoid (final concentrations of 10 mM apigenin and 2 mM luteolin) was 
mixed with 0.5 mg of epoxy beads in N,N-dimethylformamide (DMF) containing K2CO3, which 
included a tenfold molar excess of flavonoid at 37°C overnight, and washed twice with 50% DMF 
and once with deionized water. Then, the beads were washed three times with 50% methanol 
(MeOH). The beads were suspended in 50% MeOH and stored at 4°C. 
 
 Purification of flavonoid-binding proteins 
Flavonoid-fixed or control (unfixed) beads were mixed with HEK293 or U2OS cells nuclear extracts 
at 4°C for 4 h. After magnetic separation by washing thoroughly with 100 mM KCl buffer [20 mM 
HEPES-NaOH (pH 7.9), 100 mM KCl, 1 mM MgCl2, 0.2 mM CaCl2, 0.2 mM EDTA, 10% glycerol, 
0.1% Nonidet P-40 (NP-40), 1 mM DTT, and 0.2 mM PMSF], the beads were subjected to sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis and silver staining. To 
identify the flavonoid-binding proteins, LC-MS/MS analysis was performed by Q Exactive Plus 
(Thermo Fisher Scientific, Waltham, MA). The outputs of the LC-MS/MS analysis were 
prot_matches and prot_score. Prot_matches are the numbers of peptides identified (Tables S1 and 
S2). Prot_score was calculated using Mascot software (Matrix Science, London, UK). Protein 
scores shown in Figure S3B, and Tables S1 and S2 were calculated by subtracting the prot_score 
of the control from that of apigenin or luteolin. 
 
Silver staining 
The protein samples were mixed with 4× SDS buffer [190 mM Tris-HCl (pH 6.8), 40% glycerol, 0.8% 
SDS, 0.2% bromophenol blue, and 40 mM DTT] and boiled for 2 min. Protein separation was 
performed using SuperSep™ Ace, 5%–20%, 17-well (Wako). Silver staining of SDS-PAGE gels was 
carried out with Silver Staining Kit Protein (GE Healthcare, Little Chalfont, UK), in accordance with 




Total cell extracts were prepared using RIPA buffer [25 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% 
NP-40, 1% sodium deoxycholate, 0.1% SDS, 0.2 mM PMSF and 0.5 mM DTT]. The total cell 
extracts and nuclear extracts were separated by SDS-PAGE and then electrotransferred to 
FluoroTrans PVDF Transfer Membranes (Pall, Ann Arbor, MI) using a Bio-Rad Trans-Blot cell (Bio-
Rad, Hercules, CA). The blotted PVDF membrane was blocked with 5% skim milk/PBS containing 
0.1% Tween 20 for 1 h at room temperature and reacted with the primary antibody with rotation at 
4°C overnight. Blots were washed three times with PBS containing 0.1% Tween 20 for 10 min each 
and then incubated with horseradish peroxidase (HRP)-conjugated secondary antibody with rotation 
 at room temperature for 2 h. The blotted membranes were washed with PBS containing 0.1% 
Tween 20 for 10 min three times each, reacted with chemiluminescence reagent (Millipore, 
Darmstadt, Germany), and detected with the image analyzer LAS 4000 mini (GE Healthcare). 
 
Docking studies 
Molecular docking of apigenin and luteolin against the human SF3B1 was carried out using Molegro 
Virtual Docker ver. 6.0.1 (CLC bio, Aarhus, Denmark). The ligand structures were drawn by Marvin 
Sketch 5.11.5. The crystal structure of human SF3B1 bound to E7107 was downloaded from RCSB 
Protein Data Bank (PDB code: 5ZYA) and imported into the docking program according to the 
software’s instructions, by removing all ligands and accessory molecules. Potential ligand-binding 
sites of proteins were calculated using the Molegro cavity detection algorithm. All parameters were 
set to default.  
 
Total and cytoplasmic RNA isolation 
U2OS cells (20% confluence) treated with or without flavonoids were recovered by trypsinization. 
Total RNA was isolated by Sepasol-RNA I Super G (Nacalai Tesque, Kyoto, Japan), in accordance 
with the manufacturer’s instructions. 
For cytoplasmic RNA preparation, the cells recovered by trypsinization were treated with lysis 
buffer [20 mM Tris-HCl (pH 8.0), 200 mM NaCl, 1 mM MgCl2, 1% NP-40] on ice for 5 min. The 
cytoplasmic fraction was isolated by brief spinning. RNA in the cytoplasmic fraction was isolated by 
Sepasol-RNA I Super G, in accordance with the manufacturer’s instructions. 
 
Reverse transcription-polymerase chain reaction (RT-PCR) 
Complementary DNA (cDNA) was synthesized from the extracted RNA using ReverTraAce (Toyobo, 
Osaka, Japan) and random 9-mer primer, in accordance with the manufacturer’s instructions. PCR 
was performed using KOD FX Neo (Toyobo). The PCR products were visualized by a FAS-IV gel 
imaging system (Nippon Genetics, Tokyo, Japan). Amplified products were confirmed by 
sequencing. Quantitative RT-PCR (RT-qPCR) was performed with TB Green Premix Ex Taq II 
(Takara, Otsu, Japan) and analyzed on a Thermal Cycler Dice Real-Time System II (Takara). Each 
cDNA sample was prepared in triplicate. TATA-binding protein (TBP) was used to normalize each 
 sample. The amount of each mRNA was evaluated by threshold cycle (Ct) values. The relative 
levels of each mRNA were evaluated by the values of 2ˆ[Ct (TBP) − Ct (each mRNA)]. Primer sets 
used in this study are listed in Table S3. 
 
Assay for mini gene reporter fused β-globin FISH probe tag 
U2OS cells on coverslips in a 12-well plate (20% confluence) were transfected with mini gene 
reporter fused β-globin FISH probe tag using Lipofectamine 2000 (Thermo Fisher Scientific), in 
accordance with the manufacturer’s protocol, and cultured for 6 h. Then, each compound was 
added, and cells were further cultured for 24 h. Cells were fixed with 10% formaldehyde in PBS for 
20 min and permeabilized with 0.1% Triton X-100 in PBS for 10 min. Cells were washed three times 
with PBS for 10 min to remove the detergent, once with 1× SSC containing 50% formamide for 5 
min to exchange the buffer content, and hybridized with a FISH probe labeled at the 5’ end with 
Alexa Fluor 546 (5’-cttcatccacgttcaccttgccccacagggcagtaacggcagacttctcctcaggagtcaggtgcaccat-3’) 
overnight at 37°C in a humidified chamber. Cells were washed twice for 15 min at 42°C with 1× 
SSC/50% formamide and then washed for 5 min at 42°C with 2× SSC. Cells were prehybridized 
with ULTRAhyb-Oligo Hybridization Buffer for 1 h at 42°C in a humidified chamber, and then 
incubated overnight with 10 pmol Alexa Fluor 594-labeled oligo-dT45 probe diluted with hybridization 
buffer. Cells were washed for 20 min each at 42°C with 2× SSC, 0.5× SSC, and 0.1× SSC. The 
nuclei were visualized with DAPI. 
 
Mini gene splicing assay 
The β-globin reporter was kindly provided by Michael Antoniou, Ph.D. (Antoniou et al., 1998) The β-
globin gene was amplified using this reporter. The amplified product was digested with KpnI and 
HindIII and then cloned into the KpnI and HindIII sites of pcDNA5/FRT/TO vector (Invitrogen, 
Carlsbad, CA). The genomic fragment of the apigenin- and luteolin-target gene was amplified from 
human genome DNA by PCR using KOD FX Neo (Toyobo). The amplified product was digested 
with BamHI and XhoI, and then cloned into the BamHI and XhoI sites of pcDNA5/FRT/TO vector 
using the wild type as a template; mutations were introduced by two-step PCR, as illustrated in 
Figures 6B, 6C, and S6. These mini genes were confirmed by sequencing. U2OS cells (20% 
confluence) in a six-well plate were cultured for 24 h after inoculation, and then transfected with 
 mini gene using Lipofectamine 2000 (Thermo Fisher Scientific), in accordance with the 
manufacturer’s protocol, and cultured for 6 h. Then, each compound was added, and cells were 
cultured for 24 h. cDNA was synthesized from total RNA using ReverTraAce (Toyobo) and random 
9-mer primer, in accordance with the manufacturer’s instructions. PCR was performed using 
pcDNA5/FRT/TO-specific primers. The amplified products were separated by 1.0% agarose gel or 
8.0% polyacrylamide gel. Primer sets for this analysis are described in Table S3. The PCR products 
were visualized by a FAS-IV (Nippon Genetics). Band intensity was quantified by ImageJ, in 
accordance with the instructions. 
 
MTT assay 
Cell proliferation was assayed colorimetrically by 3-(4,5-di-methylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, yellow tetrazole (MTT) (Sigma-Aldrich) assay. The cells were 
inoculated at 8 × 103 cells/mL in a 96-well plate and cultured for 24 h. The test samples were added 
to each cell culture well and incubated for 24, 48, or 72 h. After 5 μL of MTT reagent (5 mg/mL) had 
been added to each well, the cells were incubated for 4 h. The cell culture plate was centrifuged at 
400×g for 5 min, after which the supernatant was removed. Then, the cells were solubilized with 10 
mM NH4Cl containing 10% SDS (pH 7.0). Cell proliferation was estimated by measuring the optical 
absorbance at 600 nm. 
  
Preparation of RNA-seq library 
U2OS cells were treated with DMSO, 75 μM apigenin, or 75 μM luteolin for 24 h and then 
harvested. Total RNA was extracted from them with Sepasol-RNA I Super G. RNA-seq library was 
prepared using Truseq Stranded mRNA Library Prep Kit (Illumina, San Diego, CA). RNA-seq was 
conducted with two biological replicates from each group using NextSeq High Output (Illumina).  
 
RNA-seq and global splicing analysis 
The obtained sequence reads were mapped to the human hg38 genome using STAR (version 
2.5.2b) (Dobin et al., 2013). Alternative splicing analysis was performed by rMATS (version 3.2.5) 
(Shen et al., 2014). Nonsignificant splicing events were filtered out using the threshold of false 
discovery rate (FDR) < 0.05. Gene ontology (GO) analysis was performed using Database for 
 Annotation, Visualization and Integrated Discovery (DAVID: version 6.7) (Huang et al., 2009a, 
2009b). Integrative Genomics Viewer (IGV: version 2.3) 
(http://software.broadinstitute.org/software/igv/home) was used for visualization of the mapping 
results. Events with an FDR less than 0.05 were defined as significant splicing events, and these 
events were analyzed by RT-PCR, RT-qPCR, and bioinformatic analysis. Splice site score was 
calculated using MaxEntScan (Yeo and Burge, 2004). BPS score was calculated using the SVM-BP 
program (Corvelo et al., 2010). 
 
siRNA or plasmid transfection 
Transfection of siRNA or pcDNA3.1-FLAG-SF3B1 (Item # 82576, obtained from Addgene, Watertown, 
MA) was performed using Lipofectamine 2000 (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. The knockdown was performed for 48 h in SF3B1 and for 40 h in TAP. 
EGFP siRNA was used as a control. The sequence of siRNAs used in this study is listed in Table S4. 
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